What is Aileron Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aileron Therapeutics's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aileron Therapeutics's Operating Income for the
three
months ended in Mar. 2024 was $ -7.21 Mil. Aileron Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Aileron Therapeutics has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Aileron Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aileron Therapeutics (NAS:ALRN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Aileron Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-7.21 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.00 Mil.
Aileron Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Aileron Therapeutics had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Aileron Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
Aileron Therapeutics (Aileron Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
285 Summer Street, Unit 101, Boston, MA, USA, 02210
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.
Executives
| James Brian Windsor |
officer: See Remarks |
2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746 |
| William Fairey |
director |
C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043 |
| Alan A Musso |
director |
FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Susan L. Drexler |
officer: See Remarks |
630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
| Muneer A Satter |
10 percent owner |
C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611 |
| Reinhard J. Ambros |
director |
C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139 |
| Von Rickenbach Josef H |
director |
C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163 |
| Jeffrey Allen Bailey |
director |
BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
| Vojo Vukovic |
officer: SVP, Chief Medical Officer |
C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421 |
| Kathryn Gregory |
officer: SVP, Chief Business Officer |
305 THAYER POND ROAD, WILTON CT 06897 |
| William Mckee |
director |
|
| Nolan Howard Sigal |
director |
941 BERRY AVENUE, LOS ALTOS CA 94024 |
| Novartis Bioventures Ltd |
10 percent owner |
C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000 |
| Rick Wanstall |
officer: VP, Finance and Operations |
C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472 |
| Longenecker John P Phd |
officer: President and CEO |
10445 PACIFIC CENTER CT, SAN DIEGO CA 92121 |
Aileron Therapeutics (Aileron Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALRN has been successfully added to your 